Concentration of beta2-microglobulin and percentage of CD4 lymphocytes in peripheral blood in patients with chronic HCV infection during IFN-alpha therapy
Tadeusz Wojciech Łapiński, Aldona Kot, Danuta ProkopowiczMed Sci Monit 2002; 8(7): CR538-542 :: ID: 510717
Abstract
Background: We evaluated the serum β2,-MG concentration and CD4 lymphocytes in the blood of HCV infected patients during IFN-α therapy, searching for a correlation between β2,-MG concentration, CD4 lymphocytes, and therapy effectiveness, as well as morphological changes in the liver.
Material/Methods: patients with chronic HCV infection were treated with IFN-α2a. The serum β2,-MG concentration was measured with the use of a method based on the fluorescent modification of the immunoenzymatic technique. The percentage of T CD4 lymphocytes in the blood was measured by direct immunofluorescence using monoclonal antibodies.
Results: The number of CD4 lymphocytes in the blood was lower in the HCV infected patients (864/ml; preferred values from 1,300 to 2,100/ml), the β2,-MG concentration was elevated (2.37 mg/dl) in comparison to the preferred values (1.52 mg/dl; p<0.05). IFN-α therapy caused an increase in the β2,-MG. The highest increase was observed among patients who did not eliminate the virus (from 2.39 to 4.10 mg/dl). In the initial period of interferon therapy an increase was observed (from 729 to 1082/ml) in the number of CD4 lymphocytes among those patients who eliminated the virus and a decrease (from 947 to 853/ml) in the patients who were not treated successfully.
Conclusions: A significant increase in β2,-MG during interferon therapy in patients with chronic HCV infection is a predictor of poor outcome. An increase in the number of CD4 lymphocytes in the initial phase of treatment suggests a positive outcome.
Keywords: IFN-α therapy, HCV infection, β2-MG
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
06 Mar 2024 : Clinical Research
Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan ...Med Sci Monit In Press; DOI: 10.12659/MSM.943884
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952